drug
(amoxicillin + omeprazole magnesium+ rifabutin) DR
Marketedupdated 3mo agoby $RDHL RedHill Biopharma Ltd.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 1, 2027
~1.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- May 27, 2042method-of-use (U-3816)US 11878011
- Feb 12, 2034formulationUS 10238606
- Feb 12, 2034formulationUS 11135172
- Feb 12, 2034formulationUS 11931463
- Feb 12, 2034formulationUS 9050263
- Feb 12, 2034formulationUS 9498445
- Feb 12, 2034formulationUS 9603806
FDA exclusivities (2)
- Nov 1, 2027GAINGAIN Antibiotic (5y)1.2y
- Nov 1, 2022NPNP
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that